Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based D...( Collaboration to Focus on the Deve...),Health

Collaboration to Focus on the Development of MicroRNA-Based Tests for

Oncology and Women's Health Indications

REHOVOT, Israel and JERSEY CITY, New Jersey, June 25 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG), announced today a collaboration with the Rabin Medical Center in Israel to develop microRNA-based diagnostics in the fields of oncology, gynecology, and obstetrics. The collaboration will leverage microRNAs' significant potential as highly sensitive and specific biomarkers, to develop a wide range of diagnostic and prognostic tests. This is the company's first collaboration to include a focus on diagnostics for women's health indications.

"MicroRNAs' unique characteristics as sensitive and specific biomarkers, coupled with our strong development engines, enable us to expand and advance our development programs outside the oncology field," said Amir Avniel, President and CEO of Rosetta Genomics. "There is true unmet medical need for better diagnostics in Women's Health, and I am confident that The Rabin Medical Center's world-renowned researchers will assist us in bringing better diagnostics to patients worldwide."

"As a leading research and clinical center at the forefront of science, we understand the importance of transforming cutting-edge technologies into next-generation products that will benefit patients worldwide," said Dr. Eyran Halpern, CEO of the Rabin Medical Center. "MicroRNAs are proving to be highly effective biomarkers for a wide range of indications. I believe that by leveraging the proprietary technologies developed by Rosetta Genomics, this collaboration will be a fruitful one."

"This collaboration is an important step towards improving women's health
'/>"/>